Skip to content

A Pilot Study of the Effect of the Combination of Inhaled Nitric Oxide and Prone Position Under EIT Monitoring on Efficacy in Patients with ARDS

A Pilot Study of the Effect of the Combination of Inhaled Nitric Oxide and Prone Position Under EIT Monitoring on Efficacy in Patients with ARDS

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06741137
Enrollment
30
Registered
2024-12-18
Start date
2024-01-01
Completion date
2025-12-31
Last updated
2025-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS

Brief summary

Investigating the Impact of Combined Inhaled Nitric Oxide and Prone Positioning on the Efficacy in ARDS Patients

Interventions

PROCEDUREinhaled nitric oxide combined with prone position ventilation

inhaled nitric oxide combined with prone position ventilation

Sponsors

Northern Jiangsu People's Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Age 18-80 years; 2. Patients with moderate to severe ARDS on mechanical ventilation

Exclusion criteria

1. Patients with severe asthma or acute exacerbation of chronic obstructive pulmonary disease (COPD), lung tumors, post-lung resection, and post-lung transplantation. 2. Patients with hemodynamic instability requiring vasopressor support: dopamine or dobutamine \>15 µg/kg/min, norepinephrine \>0.3 µg/kg/min. 3. Cardiogenic pulmonary edema. 4. Patients with severe facial deformities, facial trauma, or severe thoracoabdominal trauma that precludes prone positioning ventilation. 5. Mid to late pregnancy. 6. Patients with a history of malignancy or other irreversible diseases/conditions, including those in the terminal stage. 7. Patients expected to be discharged soon or requiring invasive mechanical ventilation for less than 24 hours. 8. Patients currently participating in other studies.

Design outcomes

Primary

MeasureTime frame
Intratidal gas distribution12 hours

Countries

China

Contacts

Primary ContactChuanqing Zhang Study Director
1504572590@qq.com1504572590

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026